Analyst consensus rating
Janux Therapeutics Analyst Rating: Strong Buy
Direct answer
Janux Therapeutics's consensus rating is Strong Buy.
17 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $36.24.
Forecast evidence checked October 17, 2026.
Get free Janux Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $16.51
- Average price target
- $36.24
- High price target
- $75.00
- Low price target
- $14.00
- Low target gap
- -15.2%
- Target upside
- +119.5%
- High target gap
- +354.3%
- Target range width
- 369.5%
- Consensus rating
- Strong Buy
- Analysts
- 17
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Janux Therapeutics?
Janux Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $36.24.
How far are Janux Therapeutics's low and high targets from the recorded price?
The low target implies -15.2%, while the high target implies +354.3%.
How many analysts are included in Janux Therapeutics's consensus?
The verified consensus includes 17 analysts.
How is Janux Therapeutics's target upside or downside calculated?
The average target of $36.24 is divided by the recorded price of $16.51, then one is subtracted to produce +119.5%. This does not guarantee a future return.
When was Janux Therapeutics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.